Patents by Inventor Isabelle Riviere

Isabelle Riviere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240124601
    Abstract: Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.
    Type: Application
    Filed: June 8, 2023
    Publication date: April 18, 2024
    Inventors: Isabelle Riviere, Ouathek Ouerfelli, Xiuyan Wang, Frances Weis-Garcia
  • Publication number: 20240124602
    Abstract: Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.
    Type: Application
    Filed: June 8, 2023
    Publication date: April 18, 2024
    Inventors: Isabelle Riviere, Ouathek Ouerfelli, Xiuyan Wang, Frances Weis-Garcia
  • Publication number: 20240066148
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Application
    Filed: January 26, 2023
    Publication date: February 29, 2024
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Michel Sadelain, Isabelle Riviere, Jorge Mansilla-Soto, Xiuyan Wang, George Stamatoyannopoulos, John Stamatoyannopoulos, Mingdong Liu
  • Publication number: 20230416392
    Abstract: Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.
    Type: Application
    Filed: June 8, 2023
    Publication date: December 28, 2023
    Inventors: Isabelle Riviere, Ouathek Ouerfelli, Xiuyan Wang, Frances Weis-Garcia
  • Publication number: 20230346938
    Abstract: The presently disclosed subject matter provides chimeric antigen receptors (CARs) that specifically target CD19 and cells comprising such CD19-targeted CARs. The presently disclosed subject matter further provides uses of the CD19-targeted CARs for treatment, e.g., for treating blood cancer.
    Type: Application
    Filed: October 24, 2022
    Publication date: November 2, 2023
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORAIL HOSPITAL FOR CANCER AND ALLIED DISEASES, MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Judith FEUCHT, Jorge MANSILLA-SOTO, Isabelle RIVIERE, Michel SADELAIN, Loic VINCENT, Gary SHAPIRO, Mei Rosa NG, Dan TAVARES, Xingyue HE
  • Patent number: 11717579
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: August 8, 2023
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Michel Sadelain, Isabelle Riviere, Jorge Mansilla-Soto, Xiuyan Wang, George Stamatoyannopoulos, John Stamatoyannopoulos, Mingdong Liu
  • Patent number: 11673961
    Abstract: Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: June 13, 2023
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Isabelle Riviere, Ouathek Ouerfelli, Xiuyan Wang, Frances Weis-Garcia
  • Publication number: 20210107987
    Abstract: Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.
    Type: Application
    Filed: February 19, 2019
    Publication date: April 15, 2021
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Isabelle Riviere, Ouathek Ouerfelli, Xiuyan Wang, Frances Weis-Garcia
  • Publication number: 20190099447
    Abstract: Provided are methods and compositions for providing early cell therapy options to subjects, offering the potential benefit of avoiding higher risk treatment modalities.
    Type: Application
    Filed: December 3, 2018
    Publication date: April 4, 2019
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Jae H. Park, Isabelle Riviere, Xiuyan Wang, Terence Purdon, Michel Sadelain, Renier J. Brentjens
  • Publication number: 20170173185
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Michel Sadelain, Isabelle Riviere, Jorge Mansilla-Soto, Xiuyan Wang, George Stamatoyannopoulos, John Stamatoyannopoulos, Mingdong Liu
  • Patent number: 6544771
    Abstract: Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.
    Type: Grant
    Filed: June 2, 1994
    Date of Patent: April 8, 2003
    Assignees: Cell Genesys, Inc., Whitehead Institute for Biomedical Research
    Inventors: Isabelle Rivière, Lawrence K. Cohen, Brad Guild, Lori F. Rafield, Paul Robbins, Richard C. Mulligan
  • Patent number: 6232772
    Abstract: A device for measuring the rotation of a rotating element comprising an encoder element rotating with the rotating element and a sensor unit connected to a stationary element. A scraping element cooperates with a surface of the encoder element in order to eliminate contaminating particles present on the surface of the encoder element. The scraping element may be carried on the sensor device and may be biased against the encoder element by an elastic device or by magnetism.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: May 15, 2001
    Assignee: The Torrington Company
    Inventors: Bernard Liatard, Rene Nantua, Isabelle Riviere
  • Patent number: 6140111
    Abstract: Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 31, 2000
    Assignees: Whitehead Institute for Biomedical Research, Cell Genesys, Inc.
    Inventors: Isabelle Riviere, Lawrence K. Cohen, Brad Guild, Lori F. Rafield, Paul Robbins, Richard C. Mulligan